Abstract: Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.

Abstract: Methods for treating dyspnea with therapeutic renal neuromodulation and associated system and methods are disclosed herein. One aspect of the present technology, for example, is directed to methods that block, reduce, and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry therapeutic benefits for patients with dyspnea.

Abstract: Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Abstract: Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.

Abstract: Methods for treating dyspnea with therapeutic renal neuromodulation and associated system and methods are disclosed herein. One aspect of the present technology, for example, is directed to methods that block, reduce, and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry therapeutic benefits for patients with dyspnea.

Abstract: Methods for treating dyspnea with therapeutic renal neuromodulation and associated system and methods are disclosed herein. One aspect of the present technology, for example, is directed to methods that block, reduce, and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry therapeutic benefits for patients with dyspnea.

Abstract: Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Abstract: Provided is a system for creating an arteriovenous flow pathway in a patient, comprising: a vessel-to-vessel guidewire; a needle delivery device constructed and arranged to place the vessel-to-vessel guidewire from a starting vessel to a target vessel; a flow creation device constructed and arranged to be advanced over the vessel-to-vessel guidewire and to create a flow pathway between the starting vessel and the target vessel; and a stent for positioning in a vessel. At least one of the starting vessel or the target vessel is a vein, and the other of the starting vessel or the target vessel is an artery. The stent is constructed and arranged to be positioned in the vein and to at least one of prevent or treat venous stenosis.

Abstract: Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Abstract: Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Abstract: Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Abstract: A medical device and associated method for delivery of a cardiac therapy that includes determining a first impedance signal along a thoracic electrode vector extending within a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector extending outside the thoracic cavity, comparing first amplitude measurements corresponding to the first impedance signals and second amplitude measurements corresponding to the second impedance signals, comparing first slope measurements corresponding to the first impedance signals and second slope measurements corresponding to the second impedance signals, and determining delivery of the cardiac therapy in response to the comparing.

Abstract: Methods, devices, and systems for carotid body modulation via accessing a target site with an endovascular approach through a superficial temporal artery.

Abstract: A medical device and associated method for delivery of a cardiac therapy that includes determining a first impedance signal along a thoracic electrode vector extending within a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector extending outside the thoracic cavity, comparing first amplitude measurements corresponding to the first impedance signals and second amplitude measurements corresponding to the second impedance signals, comparing first slope measurements corresponding to the first impedance signals and second slope measurements corresponding to the second impedance signals, and determining delivery of the cardiac therapy in response to the comparing.

Abstract: A medical device and associated method for monitoring a fluid status of a patient that includes determining a first impedance signal along an electrode vector comprising a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector, and determining a fluid status measurement in response to the determined first impedance signal and the determined second impedance signal

Abstract: Methods for treating dyspnea with therapeutic renal neuromodulation and associated system and methods are disclosed herein. One aspect of the present technology, for example, is directed to methods that block, reduce, and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry therapeutic benefits for patients with dyspnea.

Abstract: A blood volume control method has been developed including: monitoring a condition of a patient (such as hematocrit (Hct)), wherein the condition is indicative of blood volume in the patient; automatically determining that the condition indicates a low blood volume in the patient; automatically infusing an infusion solution into the patient in response to the determination of a low blood volume, and automatically adjusting the infusion to maintain the monitored condition at a predetermined value.

Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.

Abstract: Methods for therapeutic renal neuromodulation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states, including, without limitation, sleep apnea.

Abstract: Methods for therapeutic renal neuromodulation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states, including, but without limitation, insulin resistance, diabetes and/or metabolic syndrome.